Anti-amyloid-β disease-modifying therapies for Alzheimer′s disease: the dawn of a new era
10.3760/cma.j.cn113694-20230629-00427
- VernacularTitle:阿尔茨海默病靶向Aβ疾病修饰治疗：曙光初现
- Author:
Yuyuan HUANG
1
;
Jintai YU
Author Information
1. 复旦大学附属华山医院神经内科 国家神经疾病医学中心，上海 200040
- Keywords:
Alzheimer disease;
Amyloid-beta;
Clinical trial;
Disease-modifying therapies
- From:
Chinese Journal of Neurology
2023;56(9):959-964
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer′s disease (AD) is the most common neurodegenerative disease. Its etiology and pathogenesis remain unclear. Since its inception, the amyloid-β (Aβ) cascade hypothesis has dominated the field of AD research and has provided the intellectual framework for disease-modifying therapies. Nowadays, many Aβ-targeted therapies have been accelerated approval or received Food and Drug Administration′s breakthrough therapy designation which offers a new dawn for disease-modifying treating AD. This article reviews the research progress of clinical trials of Aβ-targeting modification therapies, and summarizes the lessons learned from the clinical failure with several classes of anti-Aβ drugs. Although many challenges remain, anti-Aβ therapies have become a promising treatment strategy for AD.
